Slimming medicine in Sweden 2026: all options in one row

March 20

The range of diet pills has changed more in the last three years than in the previous thirty. New GLP-1 drugs like Ozempic and Wegovy have shifted the whole conversation about weight loss from willpower to pharmacology, and new preparations like Mounjaro add another layer of possibilities. But what weight loss medicine is actually available in Sweden right now? Which are prescription, which require a specialist, and which diet pills work do we actually have data on? Here we gather all approved and actually available options — from injections to tablets and capsules — in one review.

Ozempic, Wegovy and Rybelsus — semaglutide in three forms

Semaglutide dominates the landscape. Ozempic (0.5–1.0 mg/week) is formally approved for type 2 diabetes but is widely prescribed off-label for weight loss. Wegovy (2.4 mg/week) is the dedicated weight loss variant, approved for adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities. Rybelsus (oral tablet, 14 mg/day) provides an injection-free route but with lower average weight loss.

Clinical Results: Wegovy delivers an average of 14-16% weight loss over 68 weeks in the STEP studies. Ozempic in the diabetes dose gives 7–12% depending on the dose and duration of treatment. Rybelsus lands at about 5-8% weight loss, limited in part by the lower bioavailability of the oral formulation — less than 1% of the tablet’s semaglutide reaches the bloodstream, requiring a higher nominal dose to compensate.

Accessibility has been a challenge in Sweden. During 2024–2025, periodic shortage situations arose for Ozempic and Wegovy, which forced patients to switch preparations or pause treatment. As of early 2026, the situation has stabilized somewhat, but supply disruptions may still occur locally at individual pharmacies.

How much does semaglutide treatment cost in Sweden in 2026?

Prices vary depending on prescription and subsidy status. Wegovy is included in the drug benefit for patients with a BMI ≥35 (or ≥30 with type 2 diabetes), which lowers the cost to the high-cost cover ceiling. Without subsidy, the price is around SEK 2,000–3,000 per month. Ozempic is subsidized for diabetic patients. Rybelsus costs about the same as Ozempic but is taken daily. Want to know more about Wegovy specifically? Read our guide on Wegovy in Sweden for current prices and availability information.

Mounjaro (tirzepatide) — the dual GLP-1/GIP agonist

Mounjaro represents the next generation in slimming medicine. Tirzepatide activates both GLP-1 and GIP receptors, providing stronger appetite suppression and potentially greater weight loss than semaglutide alone. The SURMOUNT-1 study showed an average weight loss of a whopping 20.9% with the highest dose (15 mg) over 72 weeks — a result that surpasses all previously published studies of single drugs.

In Sweden, tirzepatid was initially approved for type 2 diabetes under the brand name Mounjaro. Approval for weight loss (under the Zepbound brand in the US) is still being processed in Europe through the EMA as of 2026. However, many Swedish doctors are already prescribing Mounjaro off-label for weight loss in selected patients.

The side effect profile is similar to semaglutide: nausea, vomiting, diarrhea and constipation are most common during dose escalation. Escalation takes 20 weeks from the starting dose of 2.5 mg to the maximum dose of 15 mg — a slower schedule than Wegovy, but justified by the stronger effect. Many Swedish patients report that the nausea is less pronounced with tirzepatid compared to semaglutide at comparable levels of weight loss, but there are still no direct comparative studies to confirm this. Our detailed review of Mounjaro, tirzepatid and price covers everything from dosage to Swedish experiences.

Saxenda, orlistat, and bupropion-naltrexone — the older options

Not everyone needs or wants the newest preparations. Several older weight loss medications still have their place in the treatment arsenal, especially for patients who cannot tolerate GLP-1 agonists or who prefer another mechanism.

The table below provides an overview of all approved alternatives in Sweden as of 2026:

|Preparation|Active substance|Mechanism|Average weight loss (1 year)|Prescription status|

|Wego view|Semaglutide 2.4 mg|GLP-1 agonist| 14–16 % |Prescription|

|Ozempic|Semaglutide 0.5–1.0 mg|GLP-1 agonist| 7–12 % |Prescription (off-label)|

|Mounjaro|Tirzepatide 5–15 mg|GLP-1/GIP agonist| 15–21 % |Prescription|

|Saxon end|Liraglutide 3.0 mg|GLP-1 agonist| 7–8 % |Prescription|

|Rybelsus|Semaglutide oral 14 mg|GLP-1 agonist| 5–8 % |Prescription|

|Xenical|Orlistat 120 mg|Lipase inhibitor| 5–7 % |Prescription|

|Alli|Orlistat 60 mg|Lipase inhibitor| 3–4 % |Without a prescription|

|Mysimba|Bupropion/naltrexone|Dopamine/opioid| 5–6 % |Prescription|

Saxenda (liraglutide) is an older GLP-1 agonist that requires daily injections instead of Wegoy’s weekly dosing. Weight loss is more modest — about 7-8% — but the preparation has longer clinical experience and well-established safety data since 2015. Read more about Saxenda and weight loss if you are considering this option.

Mysimba (bupropion/naltrexone) attacks appetite via the dopamine and opioid systems in the brain. The preparation lacks the gastrointestinal side effects that GLP-1 drugs cause, but weight loss is modest (5–6%) and side effects such as nausea, headache and sleep disturbances occur. Mysimba may be of particular interest to patients who also suffer from depression, as bupropion is essentially an antidepressant — but it should never be prescribed to people with epilepsy, eating disorders, or ongoing alcohol or drug abuse.

We have described Orlistat (Xenical and Alli) in a separate article, but in short it blocks fat absorption in the intestine and produces 3-7% weight loss depending on the dose. It is the only alternative that is available without a prescription in Sweden (Alli 60 mg) and that does not require a doctor’s visit to start treatment.

How do you choose the right weight loss medication — a systematic review?

The choice of diet pill or injection depends on a combination of medical history, BMI, finances and personal preference. No single best weight loss medication is right for everyone, but there is a logical decision tree that most specialists follow.

The first step is always a medical assessment. BMI ≥30 (or ≥27 with weight-related comorbidities such as type 2 diabetes, high blood pressure or sleep apnea) is the threshold for prescription dieting in Sweden. Below that limit, lifestyle intervention — diet, exercise, behavior change — is recommended as first line, and drugs should not be prescribed except in exceptional cases.

For patients who meet the criteria, the choice often comes down to tolerance and economy:

• GLP-1 agonists (Wegovy, Mounjaro) provide the greatest weight loss but cost the most and require injections. The side effects are gastrointestinal and usually transient.

• Saxenda is suitable for those who want to try the GLP-1 mechanism but prefer lower doses, or who are waiting for access to Wegovy.

• Orlistat (Xenical/Alli) is suitable for those who want to avoid centrally acting drugs, accept modest weight loss and can adapt their diet to a low fat intake.

• Mysimba may be considered for patients with emotional eating or reward-driven overconsumption, where the dopamine and opioid mechanism may be particularly relevant.

A common question concerns long-term treatment. Studies show that the majority of patients regain some of the weight within 1-2 years after they stop using diet pills — regardless of the preparation. The STEP 4 study showed that patients who stopped taking semaglutide after 20 weeks regained two-thirds of the weight lost within a year. It suggests that pharmacological weight loss likely requires long-term — perhaps lifelong — treatment to maintain results. This insight should be considered already at the start of treatment.

Regardless of which drug is chosen, prescription dieting is always a supplement to — not a substitute for — dietary change and physical activity. The best long-term results in all studies are achieved by patients who combine pharmacology with behavioral changes. The drug makes it easier to maintain a caloric deficit, but it is the lifestyle changes that determine how much weight you keep on the day the treatment is eventually stopped.

.entry-content